Compare Innovative Industrial Properties Inc (IIPR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Recursion Pharmaceuticals Inc — how do they compare? Innovative Industrial Properties Inc trades at $57.91 (market cap $1.67B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Innovative Industrial Properties Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| IIPR | RXRX | |
|---|---|---|
Market Cap | $1.67B | $1.81B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $6.79 |
52-Week Low | $44.58 | $2.84 |
Enterprise Value | $2.21B | $1.33B |
Dividend Yield | 13.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Innovative Industrial Properties (IIPR) trades at $57.84, up 0.63% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 revenue of $63.3 million and FFO of $1.83 per share, beating estimates. Financials show strong gross margins of 88.35% but declining revenue from $266 million in 2025 to $264 million in 2026. Recent news highlights institutional buying and dividend sustainability debates amid tenant distress concerns.
Outlook remains mixed with a discounted P/E of 13.05 and high dividend yield offering value, but risks include revenue contraction, tenant diversification issues, and bearish technical trends. Analyst consensus is cautious with 36% buy ratings. The stock presents income appeal but requires monitoring of operational execution and cannabis sector volatility.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
